Parkinson's Institute

Parkinson's Institute. It is a non-profit medical research and clinical care center dedicated exclusively to the study and treatment of Parkinson's disease and related movement disorders. Founded in 1988 by renowned neurologist J. William Langston, the institute integrates cutting-edge scientific investigation with comprehensive patient care. Its mission is to discover the causes of and develop new treatments for Parkinson's disease through a unique, patient-centric model.

History

The institute was established in 1988 by J. William Langston, whose pivotal research into the MPTP-induced parkinsonism in a group of San Jose drug users provided a crucial model for the disease. Initially located in San Jose, California, it was one of the first independent organizations of its kind in the United States focused solely on Parkinson's disease. In 2014, the institute relocated its headquarters to a state-of-the-art facility in Sunnyvale, California, consolidating its research laboratories and clinical services. Its growth has been supported by collaborations with institutions like the Michael J. Fox Foundation and funding from the National Institutes of Health.

Research focus

The institute's research is broadly organized into clinical, translational, and basic science programs aimed at understanding the etiology and progression of Parkinson's disease. A major area of investigation involves the role of environmental toxins and genetics, building on the founder's work with MPTP and studies of familial forms of the disease. Scientists at the institute conduct extensive research on alpha-synuclein pathology, mitochondrial dysfunction, and neuroinflammation. The research portfolio also includes developing novel biomarkers and exploring the potential of stem cell therapy and deep brain stimulation protocols.

Clinical programs

The clinical division provides multidisciplinary care through a team of neurologists, nurses, and physical therapists specializing in movement disorders. It offers comprehensive diagnostic services, personalized medication management, and access to experimental therapies through its active participation in clinical trials sponsored by entities like the Parkinson's Study Group. The institute runs specialized programs for managing dyskinesia, gait disorders, and non-motor symptoms such as REM sleep behavior disorder. Its care model emphasizes long-term patient relationships to track disease progression and tailor interventions.

Notable achievements

Researchers at the institute were instrumental in characterizing the clinical and pathological features of MPTP-induced parkinsonism, a discovery that revolutionized the field. The institute's scientists have made significant contributions to understanding the LRRK2 gene and its role in familial Parkinson's disease. Its clinicians have pioneered advanced care protocols for managing motor complications and have been active in pivotal trials for medications like rasagiline and apomorphine. The institute's biorepository, containing thousands of patient samples, is a critical resource for global research efforts coordinated with the Michael J. Fox Foundation.

Organizational structure

The institute operates as an independent 501(c)(3) non-profit organization governed by a board of directors comprising leaders from the scientific, medical, and business communities, such as Silicon Valley. Its scientific direction is led by a chief scientific officer overseeing multiple laboratory heads and principal investigators. The clinical division is managed by a medical director who coordinates the activities of the movement disorders neurologists and the clinical trials unit. The institute maintains strategic partnerships with academic centers including Stanford University and the University of California, San Francisco for collaborative research and training fellows.